middle.news

How Resonance Health’s Clinical Trials and SaMD Contracts Are Driving Growth

10:12am on Thursday 31st of July, 2025 AEST Healthcare
Read Story

How Resonance Health’s Clinical Trials and SaMD Contracts Are Driving Growth

10:12am on Thursday 31st of July, 2025 AEST
Key Points
  • Receipts from customers total $2.7M with $0.2M net positive operating cashflow
  • First ten patients dosed in $13.8M major pharma clinical trial on schedule
  • TrialsWest expands to three profitable clinical trial sites in Western Australia
  • SaMD division secures ~$4.5M in multi-year contracts with global pharmaceutical companies
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Resonance Health (ASX:RHT)
OPEN ARTICLE